GALT (Galectin Therapeutics) LT-Debt-to-Total-Asset : 4.87 (As of Dec. 2024)

View and export this data going back to 2002. Start your Free Trial

What is Galectin Therapeutics LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Galectin Therapeutics's long-term debt to total assests ratio for the quarter that ended in Dec. 2024 was 4.87.

Galectin Therapeutics's long-term debt to total assets ratio increased from Dec. 2023 (2.54) to Dec. 2024 (4.87). It may suggest that Galectin Therapeutics is progressively becoming more dependent on debt to grow their business.

Galectin Therapeutics LT-Debt-to-Total-Asset Historical Data

The historical data trend for Galectin Therapeutics's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Galectin Therapeutics LT-Debt-to-Total-Asset Chart

Galectin Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.69

1.87

2.54

4.87

Galectin Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															2.54	3.19	3.38	3.25	4.87

Galectin Therapeutics LT-Debt-to-Total-Asset Calculation

Galectin Therapeutics's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (A: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2024 )	/	Total Assets (A: Dec. 2024 )
	=	85.109	/	17.495
	=

Galectin Therapeutics's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (Q: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2024 )	/	Total Assets (Q: Dec. 2024 )
	=	85.109	/	17.495
	=

Galectin Therapeutics (NAS:GALT) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Galectin Therapeutics LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Galectin Therapeutics's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Galectin Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galectin Therapeutics Inc (NAS:GALT) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

4960 Peachtree Industrial Boulevard, Suite 240, Norcross, GA, USA, 30071

Website

https://www.galectintherapeutics.com

Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.

Executives

Harold H. Shlevin	director, officer: Chief Executive Officer	C/O GALECTIN THERAPEUTICS, INC., 4690 PEACHTREE INDUSTRIAL BLVD, STE. 240, NORCROSS GA 30071
Zordani Richard A. Jr.	director	467 N. COUNTRY RIDGE CT., LAKE ZURICH IL 60047
Kary Eldred	director	2121 RINGWOOD AVENUE, SAN JOSE CA 95131
Kevin D Freeman	director	712 LAKEWAY DRIVE, KELLER TX 76248
Joel Lewis	director	12575 ULINE DRIVE, PLEASANT PRAIRIE WI 53158
Jack W Callicutt	officer: Chief Financial Officer	75 FIFTH STREET NW STE. 313, ATLANTA GA 30308
James C Czirr	director	4908 SOUTH ASHTON COURT, SPOKANE WA 99223
10x Fund, L.p.	10 percent owner	1099 FOREST LAKE TERRACE, NICEVILLE FL 32578
Elissa J. Schwartz	director	235 SW CHURCH ST., PULLMAN WA 99163
Gilbert F Amelio	director	5835 STRASBOURG COURT, ---, RENO NV 89511
Richard E Uihlein	director, 10 percent owner	12575 ULINE DRIVE, PLEASANT PRAIRIE WI 53158
Pol F Boudes	officer: Chief Medical Officer	C/O CYMABAY THERAPEUTICS, INC., 7575 GATEWAY BLVD., SUITE 110, NEWARK CA 94560
Marc Rubin	director	C/O TITAN PHARMACEUTICALS, INC., 400 OYSTER POINT BLVD., STE 505, SAN FRANCISCO CA 94080
Gilbert S Omenn	director	AMGEN INC., ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
Peter G Traber	director, officer: President and CEO	430 THAMER LANE, HOUSTON TX 77025